OWENS & MINOR INC/VA/ false 0000075252 0000075252 2025-06-05 2025-06-05
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of the Securities Exchange Act of 1934

 

(Date of earliest event reported)

Date of Report: June 5, 2025

 

 

OWENS & MINOR, INC.

(Exact name of Registrant as specified in charter)

 

 

 

Virginia   001-09810   54-1701843
(State or other jurisdiction
of incorporation)
  (Commission
file number)
  (I.R.S. employer
identification no.)

 

10900 Nuckols Road, Suite 400,  
Glen Allen, Virginia   23060
(Address of principal executive offices)   (Zip code)

 

Post Office Box 27626,  
Richmond, Virginia   23261-7626
(Mailing address of principal executive offices)   (Zip code)

Registrant’s telephone number, including area code (804) 723-7000

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common Stock, $2 par value per share   OMI   New York Stock Exchange

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 
 


Item 1.01.

Entry Into a Material Definitive Agreement.

The disclosure set forth below under Item 1.02 of this Current Report on Form 8-K is incorporated by reference herein.

 

Item 1.02.

Termination of a Material Definitive Agreement.

As previously disclosed, on July 22, 2024, Owens & Minor, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, Rotech Healthcare Holdings Inc., a Delaware corporation (“Rotech”), Hitchcock Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Merger Sub”) and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as the representative of the equityholders of Rotech (“Representative”), pursuant to which the Company agreed to acquire Rotech on the terms and subject to the conditions therein.

On June 3, 2025, the Company, Rotech and Merger Sub mutually agreed to terminate the Merger Agreement and entered into a mutual termination agreement (the “Termination Agreement”) effective as of the execution of the Termination Agreement and receipt by Rotech (or its applicable designee) of the Termination Fee (as defined below). The mutual termination of the Merger Agreement was approved by the Company’s and Rotech’s respective Boards of Directors. In accordance with the terms of the Termination Agreement, on June 5, 2025, the Company has made a cash payment to Rotech of eighty million dollars ($80,000,000) (the “Termination Fee”). The Termination Fee is the sole and exclusive remedy of the Company for any claims in connection with the Merger Agreement, and the Company and Rotech have each waived any and all other claims in connection with the Merger Agreement and the transactions contemplated thereby.

The foregoing description of the Merger Agreement and the Termination Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Merger Agreement, which was previously filed as Exhibit 2.1 to our Current Report on Form 8-K on July 23, 2024, and the full text of the Termination Agreement, which is attached hereto as Exhibit 10.1 and incorporated by reference herein.

 

Item 8.01

Other Information

On June 5, 2025, the Company issued a press release announcing the mutual termination of the Merger Agreement. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

 

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

The following exhibits are filed herewith:

 

Exhibit    Description
10.1    Termination Agreement, dated as of June 3, 2025, by and among Owens & Minor, Inc., Rotech Healthcare Holdings Inc., and Hitchcock Merger Sub Inc.
99.1    Press Release, dated as of June 5, 2025.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

      OWENS & MINOR, INC.
Date: June 5, 2025     By:  

/s/ Heath H. Galloway

    Name:   Heath H. Galloway
    Title:   Executive Vice President, General Counsel & Corporate Secretary

Exhibit 10.1

MUTUAL TERMINATION AGREEMENT

MUTUAL TERMINATION AGREEMENT (this “Agreement”), dated as of June 3, 2025, by and among Rotech Healthcare Holdings Inc., a Delaware corporation (the “Company”), Owens & Minor, Inc., a Virginia corporation (“Parent”), and Hitchcock Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger Sub”).

W I T N E S S E T H:

WHEREAS, Parent, Merger Sub, the Company and Shareholder Representatives Services LLC, a Colorado limited liability company, solely in its capacity as representative of the Equityholders (the “Representative”), entered into that certain Agreement and Plan of Merger, dated as of July 22, 2024 (the “Merger Agreement”). Any capitalized term used but not otherwise defined herein shall have the meaning set forth in the Merger Agreement.

WHEREAS, Section 9.1(a) of the Merger Agreement provides that the Merger Agreement may be terminated at any time prior to the Closing by mutual written consent of the Company and Parent.

WHEREAS, the Boards of Directors of each of the Company and Parent have determined that it is in the best interests of their respective companies and their respective stockholders to terminate the Merger Agreement in accordance with the terms hereof.

NOW, THEREFORE, in consideration of the mutual covenants, representations, warranties and agreements contained herein, and intending to be legally bound hereby, the parties agree as follows:

 

1.

The parties hereto mutually agree to terminate the Merger Agreement, effective as of the execution of this Agreement and receipt by the Company (or its applicable designee) of the Termination Fee (as defined below) (such time, the “Termination Time”), such agreement constituting the requisite mutual agreement and written consent required to terminate the Merger Agreement pursuant to Section 9.1(a) of the Merger Agreement and otherwise as may be required pursuant to applicable Law. Parent and the Company each agree that, at the Termination Time, the Merger Agreement is hereby and forthwith void and of no further force and effect, in each case, other than the provisions of the Merger Agreement that survive the termination thereof pursuant to Section 9.2 of the Merger Agreement, which shall survive in accordance with such section, subject to the releases contained herein.

 

2.

The press release of Parent announcing the termination of the Merger Agreement pursuant to this Agreement is set forth on Annex A. Parent shall issue such press release following the Termination Time. Notwithstanding anything to the contrary herein, the terms and provisions of the Confidentiality Agreement shall survive the termination of this Agreement in accordance with the terms therein. Parent shall comply with the terms and provisions of the Confidentiality Agreement, including with respect to returning or destroying all Confidential Information.

 

3.

Each of Parent and the Company hereby represents and warrants that (a) such party has all requisite corporate power and authority to execute, deliver and perform this Agreement, (b) the execution and delivery of this Agreement, the termination of the Merger Agreement and consummation of the other transactions contemplated hereby have been duly and validly authorized by all required corporate action on the part of such party, (c) no other corporate proceedings on the part of such party are


  necessary to authorize this Agreement, the termination of the Merger Agreement or to consummate the other transactions contemplated hereby and (d) this Agreement has been duly and validly executed and delivered by such party (assuming this Agreement constitutes a legal, valid and binding obligation of the other parties hereto) and constitutes a legal, valid and binding obligation of such party, enforceable against such party in accordance with its terms except to the extent that the enforceability thereof may be limited by the Equitable Exceptions.

 

4.

This Agreement may not be amended except by an instrument in writing signed on behalf of each of the parties hereto. Waiver of any term or condition of this Agreement by any party hereto shall only be effective if in writing and shall not be construed as a waiver of any subsequent breach or failure of the same term or condition, or a waiver of any other term or condition of this Agreement.

 

5.

As liquidated damages as contemplated by Section 9.3 of the Merger Agreement and as consideration for the Company agreeing to terminate the Merger Agreement at the Termination Time and the Company agreeing to waive any other rights or remedies it may have under the Merger Agreement as set forth in Section 6 of this Agreement, Parent shall pay, or cause to be paid, to the Company as promptly as practicable following the execution of this Agreement (and in any event within two (2) Business Days following the date hereof), a payment in the amount of eighty million dollars ($80,000,000) (the “Termination Fee”) in cash by wire transfer of immediately available funds to one or more accounts designated in writing by the Company.

 

6.

The parties hereto agree that, from and after the Termination Time, other than payment of the Termination Fee and claims in connection with this Agreement, none of Parent, Merger Sub, any other Subsidiary of Parent or any of their respective former, current or future officers, directors, partners, stockholders, managers, members, Affiliates or Agents shall have any further liability whatsoever with respect to the Merger Agreement or the transactions contemplated by the Merger Agreement to the Company, any Subsidiary of the Company or any of their respective Affiliates or Agents and payment of the Termination Fee (subject to the final sentence of this Section 6) by Parent shall be the Company’s and its Affiliates’ sole and exclusive remedy for any Action, losses, liabilities, damages, judgments, inquiries, fines, fees, costs and expenses suffered or incurred by the Company, the Subsidiaries of the Company or any other Person in connection with the Merger Agreement, the transactions contemplated by the Merger Agreement (and the termination thereof) or any matter forming the basis for such termination, and the Company shall not have, and expressly waives and relinquishes, any other right, remedy or recourse (whether in contract or in tort or otherwise, or whether at law (including at common law or by statute) or in equity) against Parent or Merger Sub under the Merger Agreement and the transactions contemplated by the Merger Agreement; provided that the Confidentiality Agreement and that certain Clean Team Agreement, dated May 13, 2024 (the “Clean Team Agreement”), between the Company and Parent, shall survive termination of the Merger Agreement in accordance with their terms as and to the extent provided therein and in Section 2 of this Agreement. If Parent fails to promptly pay the Termination Fee pursuant to this Agreement and the Company commences an Action that results in a final, nonappealable judgment against Parent for the payment of the Termination Fee, Parent shall pay, or cause to be paid, to the Company interest on such amount at an annual rate equal to the prime rate as published in The Wall Street Journal, Eastern Edition, in effect on the date such amounts were originally due hereunder which shall accrue from such date through the date such payment is actually delivered to the Company or its designee, and the costs and expenses (including reasonable attorneys’ fees and expenses) incurred by the Company in connection with such Action.


7.

The parties hereto agree that, from and after the Termination Time, other than claims in connection with this Agreement, none of the Company, any other Subsidiary of the Company or any of their respective former, current or future officers, directors, partners, stockholders, managers, members, Affiliates or Agents shall have any liability whatsoever with respect to the Merger Agreement, the transactions contemplated by the Merger Agreement (and the termination thereof) or any matter forming the basis for such termination to Parent, any Subsidiary of Parent or any of its respective Affiliates or Agents, and none of Parent or Merger Sub shall have, and expressly waive and relinquish, any other right, remedy or recourse (whether in contract or in tort or otherwise, or whether at law (including at common law or by statute) or in equity) against the Company under the Merger Agreement and the transactions contemplated by the Merger Agreement; provided that the Confidentiality Agreement and the Clean Team Agreement shall survive termination of the Merger Agreement in accordance with their terms as and to the extent provided therein and in Section 2 of this Agreement.

 

8.

The parties hereto acknowledge that, at the Termination Time, the Restrictive Covenant Agreement, dated as of July 22, 2024, by and between the Company, Parent, Merger Sub and the Stockholders of the Company party thereto shall, without further action, terminate and be of no further force and effect.

 

9.

Parent and the Company have participated jointly in negotiating and drafting this Agreement. In the event that an ambiguity or a question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by Parent and the Company, and no presumption or burden of proof shall arise favoring or disfavoring any party hereto by virtue of the authorship of any of the provisions of this Agreement. When a reference is made in this Agreement to Sections or Annexes, such reference shall be to a Section or an Annex of this Agreement unless otherwise indicated. Whenever the words “include,” “includes” or “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation.” The word “or” shall not be exclusive. Each party hereto shall pay its own expenses incident to this Agreement.

 

10.

Neither this Agreement nor any of the rights, obligations or liabilities hereunder shall be assigned by any party hereto (whether by operation of law or otherwise) without the prior written consent of the other party hereto (which may be withheld by such other party in its sole discretion). Any purported assignment in contravention hereof shall be void. Subject to the preceding sentence, this Agreement will be binding upon and inure to the benefit of the parties hereto and their respective permitted successors and assigns. This Agreement (including the documents and instruments referred to herein) is not intended to confer upon any Person other than the parties hereto any rights, remedies or claims hereunder, including the right to rely upon the representations and warranties set forth herein.

 

11.

Sections 10.5, 10.7, 10.12, 10.15, 10.16, 10.17, 10.19, 10.22 and 10.24 of the Merger Agreement are hereby incorporated into this Agreement by reference, and shall apply hereto as though set forth herein, mutatis mutandis.

[Signature Page Follows]


IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their respective officers thereunto duly authorized as of the date first above written.

 

COMPANY:
ROTECH HEALTHCARE HOLDINGS INC.
By:  

/s/ Robin L. Menchen

Name:   Robin L. Menchen
Title:   President and Chief Executive Officer
PARENT:
OWENS & MINOR, INC.
By:  

/s/ Edward Pesicka

Name:   Edward Pesicka
Title:   Chief Executive Officer
MERGER SUB:
HITCHCOCK MERGER SUB INC.
By:  

/s/ Heath Galloway

Name:   Heath Galloway
Title:   General Counsel and Vice President


Annex A

Press Release

Attached.

Exhibit 99.1

Owens & Minor and Rotech Healthcare Mutually Agree to Terminate Previously Announced Acquisition

OMI Remains Committed to Continued Growth in the Strong Home-based Care Market

Will Focus on Deleveraging & Driving Profitable Growth

RICHMOND, VA – June 5, 2025 – Owens & Minor, Inc. (NYSE: OMI) today announced it has mutually agreed with Rotech Healthcare Holdings Inc. to terminate the previously announced acquisition. Under the terms of the merger agreement, Owens & Minor has paid $80 million to Rotech Healthcare. Owens & Minor will also redeem the $1 billion of notes issued in April 2025, that include a special mandatory redemption provision in accordance with their terms, and terminate the incremental term loan commitments and senior unsecured bridge loan commitments provided by our lenders that would have been utilized to consummate the acquisition.

“For many months, our teammates along with the Rotech team have worked tirelessly in cooperation with the Federal Trade Commission to close this transaction, and while we believe there would have been an ample benefits to patients, payors and providers by adding Rotech to our Patient Direct business, however, the path to obtain regulatory clearance for this merger proved unviable in terms of time, expense, and opportunity,” said Edward A. Pesicka, President & Chief Executive Officer of Owens & Minor.

“We are confident in our strategy and will continue to focus our efforts on growing our Patient Direct business while remaining committed to strengthening our balance sheet through the use of improved cash flow generation for deleveraging. The home-based care market is a dynamic, growing market and we are extremely well positioned to help those with chronic conditions get the care and service they need and deserve. Also, we continue to work with a number of interested parties around the potential sale of our Products and Healthcare Services business and in the meantime, we will continue to actively work to strengthen that business and tap into its significant upside”.

“I want to thank our teammates, partners and everyone at Rotech for their effort and cooperation over the last several months and we look forward to a bright future with many years profitable growth,” Pesicka concluded.

About Owens & Minor

Owens & Minor, Inc. (NYSE: OMI) is a Fortune 500 global healthcare solutions company providing essential products and services that support care from the hospital to the home. For over 100 years, Owens & Minor and its affiliated brands, Apria®, Byram® and HALYARD*, have helped to make each day better for the patients, providers, and communities we serve. Powered by more than 20,000 teammates worldwide, Owens & Minor delivers comfort and confidence behind the scenes so healthcare stays at the forefront. Owens & Minor exists because every day, everywhere, Life Takes Care. For more information about Owens & Minor and our affiliated brands, visit owens-minor.com or follow us on LinkedIn and Instagram.

 

*

Registered Trademark or Trademark of O&M Halyard or its affiliates.

This press release shall not constitute an offer to buy the notes issued in April 2025, which will be conducted pursuant to a special mandatory redemption in accordance with the terms of the notes.

CONTACT:

Investors

Alpha IR Group

Jackie Marcus or Nick Teves

OMI@alpha-ir.com

Media

Stacy Law

media@owens-minor.com

 

1

v3.25.1
Document and Entity Information
Jun. 05, 2025
Cover [Abstract]  
Entity Registrant Name OWENS & MINOR INC/VA/
Amendment Flag false
Entity Central Index Key 0000075252
Document Type 8-K
Document Period End Date Jun. 05, 2025
Entity Incorporation State Country Code VA
Entity File Number 001-09810
Entity Tax Identification Number 54-1701843
Entity Address, Address Line One 10900 Nuckols Road
Entity Address, Address Line Two Suite 400
Entity Address, City or Town Glen Allen
Entity Address, State or Province VA
Entity Address, Postal Zip Code 23060
City Area Code (804)
Local Phone Number 723-7000
Security 12b Title Common Stock, $2 par value per share
Trading Symbol OMI
Security Exchange Name NYSE
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company false

Owens and Minor (NYSE:OMI)
Historical Stock Chart
From Jun 2025 to Jul 2025 Click Here for more Owens and Minor Charts.
Owens and Minor (NYSE:OMI)
Historical Stock Chart
From Jul 2024 to Jul 2025 Click Here for more Owens and Minor Charts.